This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of claims:**

1. (currently amended) A compound consisting of a total of 8-50 nucleotides and/or ~~nucleotidee~~ nucleotide analogues, wherein said compound comprises a subsequence of at least 8 nucleotides or nucleotide analogues, said subsequence being located within a sequence selected from the group consisting of SEQ ID NOS: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74 or 75.

2. (currently amended) A compound of ~~according to~~ claim 1, which modulates the expression of ras selected from Ha-ras, Ki-ras or N-ras.

3. (currently amended) A compound consisting of a total of 8-50 nucleotides and/or ~~nucleotidee~~ nucleotide analogues targeted to a nucleic acid molecule encoding Ha-ras, wherein said compound specifically hybridises with a nucleic acid encoding Ha-ras and inhibits the expression of Ha-ras and wherein said compound comprises a subsequence of at least 8 nucleotides or nucleotide analogues, said subsequence being located within a sequence selected from the group consisting of SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74 or 75.

4. (currently amended) The compound according to ~~any of claims 1-3~~ claim 1, which is an antisense oligonucleotide.

5. (currently amended) The compound according to ~~any of claims 1-4~~ claim 1, comprising at least nucleotide analogue.

6. (currently amended) The compound according to ~~any of claims 1-5~~ claim 1, comprising at least one Locked Nucleic Acid (LNA) unit.

7. (currently amended) The compound according to ~~claims~~ claim 6, wherein the Locked Nucleic Acid (LNA) has the structure of the general formula




X and Y are independently selected among the groups -O-, -S-, -N(H)-, N(R)-, $-CH_2-$ or -CH- (if part of a double bond), $-CH_2-O-$, $-CH_2-S-$, $-CH_2-N(H)-$, $-CH_2-N(R)-$, $-CH_2-CH_2-$ or $-CH_2-CH-$ (if part of a double bond), -CH=CH-, where R is selected form hydrogen and $C_{1-4}$-alkyl ; Z and Z* are independently absent, selected among an internucleoside linkage, a terminal group or a protecting group;
B constitutes a natural or non-natural nucleobase;
and the asymmetric groups may be found in either orientation.

8. (original) The compound according to claim 6, wherein at least one nucleotide comprises a Locked Nucleic Acid (LNA) unit according any of the formulas









wherein Y is -O-, -S-, -NH-, or $N(R^H)$; Z and Z* are independently absent, selected among an internucleoside linkage, a terminal group or a protecting group; and B constitutes a natural or non-natural nucleobase.

9. (original) The compound according to claim 6 or 7, wherein the internucleoside linkage may be selected from the group consisting of -O-$P(O)_2$-O-, -O-P(O,S)-O-, -O-$P(S)_2$-O-, -S-$P(O)_2$-O-, -S-P(O,S)-O-, -S-$P(S)_2$-O-, -O-$P(O)_2$-S-, -O-P(O,S)-S-, -S-$P(O)_2$-S-, -O-$PO(R^H)$-O-, O-$PO(OCH_3)$-O-, -O-$PO(NR^H)$-O-, -O-$PO(OCH_2CH_2S$-R)-O-, -O-$PO(BH_3)$-O-, -O-$PO(NHR^H)$-O-, -O-$P(O)_2$-$NR^H$-, -$NR^H$-$P(O)_2$-O-, -$NR^H$-CO-O-, where $R^H$ is selected form hydrogen and $C_{1-4}$-alkyl.

10. (original) The compound according to claim 5, 6 or 7, wherein the nucleobases is a modified nucleobases selected from the group consisting of 5-methylcytosine, isocytosine, pseudoisocytosine, 5-bromouracil, 5-propynyluracil, 6-aminopurine, 2-aminopurine, inosine, diaminopurine, 2-chloro-6-aminopurine.

11. (original) The compound according to any of claims 6-8, wherein the LNA is oxy-LNA, thio-LNA, amino-LNA, in either the D-ß or L-α configurations or combinations thereof.

12. (currently amended) A compound consisting of a total of 8-50 nucleotides and/or ~~nucleotidee~~ nucleotide analogues, wherein said compound comprises a subsequence of at least 8 nucleotides or nucleotide analogues, said subsequence being located within a sequence selected from the group consisting of SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 75.

13. (currently amended) The compound according to ~~any of claims 1-12~~ claim 1, wherein the antisense oligonucleotide is a design according to any of the designs presented in Figure 1.

14. (original) The compound according to claim 12, wherein the antisense oligonucleotide is a gapmer.

15. (currently amended) The compound according to ~~any of the claims 1-14~~ claim 1, wherein the antisense oligonucleotide comprises 13, 14, 15, 16, 17, 18, 19, 20 or 21 nucleotides.

16. (currently amended) The compound according to ~~any of the claims 1-15~~ claim 1, comprising 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 LNA units.

17. (currently amended) The compound according to ~~any of the claims 1-16~~ claim 1, wherein the subsequence is SEQ ID NO: ~~2a~~ 93.

18. (currently amended) The compound according to ~~any of the claims 1-16~~ claim 1, wherein the subsequence is SEQ ID NO: ~~3a~~ 96.

19. (currently amended) The compound according to ~~any of the claims 1-16~~ claim 1, wherein the subsequence is SEQ ID NO: ~~4a~~ 99.

20. (currently amended) The compound according to ~~any of the claims 1-16~~ claim 1, wherein the subsequence is SEQ ID NO: ~~5a~~ 102.

21. (currently amended) The compound according to ~~any of the claims 1-16~~ claim 1, wherein the subsequence is SEQ ID NO: ~~6a~~ 105.

22. (currently amended) The compound according to ~~any of the claims 1-16~~ claim 1, wherein the subsequence is SEQ ID NO: ~~7a~~ 108.

23. (currently amended) The compound according to ~~any of the claims 1-16~~ claim 1, wherein the subsequence is SEQ ID NO: ~~8a~~ 111.

24. (currently amended) The compound according to ~~any of the claims 1-16~~ claim 1, wherein the subsequence is SEQ ID NO: ~~9a~~ 114.

25. (currently amended) The compound according to ~~any of the claims 1-16~~ claim 1, wherein the subsequence is SEQ ID NO: ~~10a~~ 117.

26. (currently amended) The compound according to ~~any of the claims 1-16~~ claim 1, wherein the subsequence is SEQ ID NO: ~~11a~~ 120.

27. (currently amended) The compound according to ~~any of the claims 1-16~~ claim 1, wherein the subsequence is SEQ ID NO: ~~12a~~ 123.

28. (currently amended) The compound according to ~~any of the claims 1-16~~ claim 1, wherein the subsequence is SEQ ID NO: ~~13a~~ 126.

29. (currently amended) The compound according to ~~any of the claims 1-16~~ claim 1, wherein the subsequence is SEQ ID NO: ~~14a~~ 129.

30. (currently amended) The compound according to ~~any of the claims 1-16~~ claim 1, wherein the subsequence is SEQ ID NO: ~~15a~~ 132.

31. (currently amended) The compound according to ~~any of claims 57-72~~ claim 6, wherein the 3' end LNA is replaced by the corresponding natural nucleoside.

32. (currently amended) A compound consisting of SEQ ID NO: ~~2a~~ 93.

33. (currently amended) A compound consisting of SEQ ID NO: ~~3a~~ 96.

34. (currently amended) A compound consisting of SEQ ID NO: ~~4a~~ 99.

35. (currently amended) A compound consisting of SEQ ID NO: ~~5a~~ 102.

36. (currently amended) A compound consisting of SEQ ID NO: ~~6a~~ 105.

37. (currently amended) A compound consisting of SEQ ID NO: ~~7a~~ 108.

38. (currently amended) A compound consisting of SEQ ID NO: ~~8a~~ 111.

39. (currently amended) A compound consisting of SEQ ID NO: ~~9a~~ 114.

40. (currently amended) A compound consisting of SEQ ID NO: ~~10a~~ 117.

41. (currently amended) A compound consisting of SEQ ID NO: ~~11a~~ 120.

42. (currently amended) A compound consisting of SEQ ID NO: 12a 123.

43. (currently amended) A compound consisting of SEQ ID NO: ~~13a~~ 126.

44. (currently amended) A compound consisting of SEQ ID NO: ~~14a~~ 129.

45. (currently amended) A compound consisting of SEQ ID NO: ~~15a~~ 132.

~~50~~ 46. (currently amended) The compound according to any of claims 34-45, wherein the 3' end LNA is replaced by the corresponding nucleotide.

~~51~~ 47. (currently amended) A conjugate comprising the compound according to ~~any of claims 1-50~~ claim 1 and at least one non-nucleotide or non-polynucleotide moiety covalently attached to said compound.

~~52~~ 48. (currently amended) A pharmaceutical composition comprising a compound as defined in ~~any of claims 1-51~~ claim 1 or a conjugate as defined in claim ~~59~~ 47, and a pharmaceutically acceptable diluent, carrier or adjuvant.

~~53~~ 49. (currently amended) The pharmaceutical composition according to claim ~~51~~ 48 further comprising at least one chemotherapeutic agent.

~~54~~ 50. (currently amended) The pharmaceutical composition according to claim ~~52~~ 49, wherein said chemotherapeutic compound is selected from the group consisting of adrenocorticosteroids, such as prednisone, dexamethasone or decadron; altretamine (hexalen, hexamethylmelamine (HMM)); amifostine (ethyol); aminoglutethimide (cytadren); amsacrine (M-AMSA); anastrozole (arimidex); androgens, such as testosterone; asparaginase (elspar); bacillus calmette-gurin; bicalutamide (casodex); bleomycin (blenoxane); busulfan (myleran); carboplatin (paraplatin); carmustine (BCNU, BiCNU); chlorambucil (leukeran); chlorodeoxyadenosine (2-CDA, cladribine, leustatin); cisplatin (platinol); cytosine arabinoside (cytarabine); dacarbazine (DTIC); dactinomycin (actinomycin-D, cosmegen); daunorubicin (cerubidine); docetaxel (taxotere); doxorubicin (adriomycin); epirubicin; estramustine (emcyt); estrogens, such as diethylstilbestrol (DES); etopside (VP-16, VePesid, etopophos); fludarabine (fludara); flutamide (eulexin); 5-FUDR (floxuridine); 5-fluorouracil (5-FU); gemcitabine (gemzar); goserelin (zodalex); herceptin (trastuzumab); hydroxyurea (hydrea); idarubicin (idamycin); ifosfamide; IL-2 (proleukin, aldesleukin); interferon alpha (intron A, roferon A); irinotecan (camptosar); leuprolide (lupron); levamisole (ergamisole); lomustine (CCNU); mechlorathamine (mustargen, nitrogen mustard); melphalan (alkeran); mercaptopurine (purinethol, 6-MP); methotrexate (mexate); mitomycin-C (mutamucin); mitoxantrone (novantrone); octreotide (sandostatin); pentostatin (2-deoxycoformycin, nipent);

plicamycin (mithramycin, mithracin); prorocarbazine (matulane); streptozocin; tamoxifin (nolvadex); taxol (paclitaxel); teniposide (vumon, VM-26); thiotepa; topotecan (hycamtin); tretinoin (vesanoid, all-trans retinoic acid); vinblastine (valban); vincristine (oncovin) and vinorelbine (navelbine).

~~55~~ 51. (currently amended) A pharmaceutical composition comprising the compound of ~~any of claims 1-50~~ claim 1, which further comprises a pharmaceutically acceptable carrier.

~~56~~ 52. (currently amended) A pharmaceutical composition comprising the compound of ~~any of claims 1-50~~ claim 1, which is employed in a pharmaceutically acceptable salt.

~~57~~ 53. (currently amended) A pharmaceutical composition comprising the compound of ~~any of claims 1-50~~ claim 1, which is constitutes a pro-drug.

~~58~~ 54. (currently amended) A pharmaceutical composition comprising the compound of ~~any of claims 1-50~~ claim 1, which further comprises an antiinflamatory compounds and/or antiviral compounds.

~~59~~ 55. (currently amended) Use of a compound as defined in ~~any of claims 1-50~~ claim 1 or as conjugate as defined in claim ~~51~~ 47 for the manufacture of a medicament for the treatment of cancer.

~~60~~ 56. (currently amended) Use according to claim ~~59~~ 55, wherein said cancer is in the form of a solid tumor.

~~61~~ 57. (currently amended) Use according to claim ~~59 or 60~~ 55, wherein said cancer is a carcinoma.

~~62~~ 58. (currently amended) Use according to claim ~~61~~ 57, wherein said carcinoma is selected from the group consisting of malignant melanoma, basal cell carcinoma, ovarian carcinoma, breast carcinoma, non-small cell lung cancer, renal cell carcinoma, bladder carcinoma, recurrent superficial bladder cancer, stomach carcinoma, prostatic carcinoma, pancreatic carcinoma, lung carcinoma, cervical carcinoma, cervical dysplasia, laryngeal papillomatosis, colon carcinoma, colorectal carcinoma and carcinoid tumors.

~~63~~ 59. (currently amended) Use according to claim ~~62~~ 58 wherein said carcinoma is selected from the group consisting of malignant melanoma, non-small cell lung cancer, breast carcinoma, colon carcinoma and renal cell carcinoma.

~~64~~ 60. (currently amended) Use according to claim ~~63~~ 59, wherein said malignant melanoma is selected from the group consisting of superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral melagnoma, amelanotic melanoma and desmoplastic melanoma.

~~65~~ 61. (currently amended) Use according to claim ~~60 or 61~~ 56, wherein said cancer is a sarcoma.

~~66~~ 62. (currently amended) Use according to claim ~~65~~ 61, wherein said sarcoma is selected from the group consisting of osteosarcoma, Ewing's sarcoma, chondrosarcoma, malignant fibrous histiocytoma, fibrosarcoma and Kaposi's sarcoma.

~~67~~ 63. (currently amended) Use according to claim ~~60 or 61~~ 55, wherein said cancer is a glioma.

~~68~~ 64. (currently amended) A method for treating cancer, said method comprising administering a compound as defined in ~~any of claims 1-50~~ claim 1, a conjugate as defined in

claim ~~51~~ 47 or a pharmaceutical composition as defined in ~~any of claims 52-58~~ claim 48 to a patient in need thereof.

~~69~~ 65. (currently amended) The method according to claim ~~68~~ 64, wherein said cancer is in the form of a solid tumor.

~~70~~ 66. (currently amended) The method according to claim ~~68 or 69~~ 64, wherein said cancer is a carcinoma.

~~71~~ 67. (currently amended) The method according to claim ~~70~~ 66, wherein said carcinoma is selected from the group consisting of malignant melanoma, basal cell carcinoma, ovarian carcinoma, breast carcinoma, non-small cell lung cancer, renal cell carcinoma, bladder carcinoma, recurrent superficial bladder cancer, stomach carcinoma, prostatic carcinoma, pancreatic carcinoma, lung carcinoma, cervical carcinoma, cervical dysplasia, laryngeal papillomatosis, colon carcinoma, colorectal carcinoma and carcinoid tumors.

~~72~~ 68. (currently amended) The method according to claim ~~71~~ 67, wherein said carcinoma is selected from the group consisting of malignant melanoma, non-small cell lung cancer, breast carcinoma, colon carcinoma and renal cell carcinoma.

~~73~~ 69. (currently amended) The method according to claim ~~124~~ 68, wherein said malignant melanoma is selected from the group consisting of superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral melagnoma, amelanotic melanoma and desmoplastic melanoma.

~~74~~ 70. (currently amended) The method according to claim ~~68~~ 64, wherein said cancer is a sarcoma.

~~75~~ 71. (currently amended) The method according to claim ~~74~~ 70, wherein said sarcoma is selected from the group consisting of osteosarcoma, Ewing's sarcoma, chondrosarcoma, malignant fibrous histiocytoma, fibrosarcoma, artherosclerosis, psoriasis, diabetic retinopathy, rheumatoid arthritis, asthma, warts, allergic dermatitis and Kaposi's sarcoma.

~~75~~ 72. (currently amended) The method according to claim ~~68~~ 64, wherein said cancer is a glioma.

~~76~~ 73. (currently amended) A method of inhibiting the expression of Ha-ras, in cells or tissues comprising contacting said cells or tissues with the compound according to ~~any of claims 1-50~~ claim 1 so that expression of Ha-ras is inhibited.

~~77~~ 74. (currently amended) A method of modulating expression of a gene involved in a cancer disease comprising contacting the gene or RNA from the gene with an oligomeric compound wherein said compound has a sequence comprising at least an 8 nucleobase portion of SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74 or 75 whereby gene expression is modulated.

~~78~~ 75. (currently amended) A method according to claim ~~77~~ 74, wherein the compounds comprises one or more LNA units.

~~79~~ 76. (currently amended) The method of claim ~~77 or 78~~ 74, wherein the compound hybridizes with messenger RNA of the gene to inhibit expression thereof.

~~80~~ 77. (currently amended) A method of treating a mammal suffering from or susceptible from an cancer disease, comprising:

administering to the mammal an therapeutically effective amount of an oligonucleotide targeted to Ha-ras that comprises one or more LNA units.

~~81~~ 78. (currently amended) The method according to ~~any of the claims 77-80~~ claim 73, wherein the cancer diseases is a lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancer.

~~82~~ 79. (currently amended) A method of modulating the red blood cell proliferation, cellular proliferation, ion metabolism, glucose and energy metabolism, pH regulation or matrix metabolism comprising contacting a cell with the antisense compound of claim ~~1-50~~ 1 so that the cell is modulated.

~~83~~ 80. (currently amended) A method of inhibiting the proliferation of cells comprising contacting cells in vitro with an effective amount of the antisense compound of claim ~~1-50~~ 1, so that proliferation of the cells is inhibited.

~~84~~ 81. (currently amended) The method of claim ~~83~~ 80 wherein said cells are cancer cells.

~~85~~ 82. (currently amended) A method of inhibiting the expression of Ha-ras in human cells or tissues comprising contacting human cells or tissues with the compound of claim ~~1-50~~ 1 so that expression of Ha-ras is inhibited.

~~86~~ 83. (currently amended) A method of treating an animal having a disease or condition associated with Ha-ras comprising administering to an animal having a disease or condition associated with Ha-ras a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of Ha-ras is inhibited.

~~87~~ 84. (currently amended) The method of claim ~~86~~ 83 wherein the disease or condition is a hyperproliferative condition.

~~88~~ 85. (currently amended) The method of claim ~~87~~ 84 wherein the hyperproliferative condition is cancer.

~~89~~ 86. (currently amended) A method of treating a human having a disease or condition characterized by a reduction in apoptosis comprising administering to a human having a disease or condition characterized by a reduction in apoptosis a prophylactically or therapeutically effective amount of the antisense compound of claim ~~1–50~~ 1.

~~90~~ 87. (currently amended) A method of modulating apoptosis in a cell comprising contacting a cell with the antisense compound of claim ~~1–50~~ 1 so that apoptosis is modulated.

~~91~~ 88. (currently amended) A method of modulating cytokinesis in a cell comprising contacting a cell with the antisense compound of claim ~~1–50~~ 1 so that cytokinesis is modulated.

~~92~~ 89. (currently amended) A method of modulating the cell cycle in a cell comprising contacting a cell with the antisense compound of claim ~~1–50~~ 1 so that the cell cycle is modulated.

~~93~~ 90. (currently amended) A method of inhibiting the proliferation of cells comprising contacting cells with an effective amount of the antisense compound of claim~~1–50~~ 1, so that proliferation of the cells is inhibited.